Global Markets for Marine-Derived PharmaceuticalsPublished:October 2011No.Of pages:180Price:US $ 4850INTRODUCTIONThe search for bioactive metabolites from marine microbes has only just begun”—DavidNewman, D. Phil, and Russell Hill, PhD, New Drugs from Marine Microbes: The Tide isTurning (2006)STUDY GOALS AND OBJECTIVESBCC’s goal in conducting this study was to determine the current status of the globalmarine-derived pharmaceutical market, including its growth potential during the period of2011 to 2016. Our key objective is to present a comprehensive analysis of marine life andtechnology as they relate to pharmaceutical applications and to forecast this market’s futuredirection.REASONS FOR DOING THIS STUDYOur understanding of marine life only began during the last half of the 20th century. Thefirst marine discovery that led to a pharmaceutical drug began in the 1950s when chemistsBergmann and Feeney isolated nucleosidic compounds from the Caribbean spongeCryptotethya crypta. Marine drugs on the market today can be traced to this discovery(e.g., anticancer drug cytarabine).While marine life is used for many applications, including food and industrial processing, itsuse in the pharmaceutical industry has just begun. Marine life offers a complex and diversegenetic resource unavailable on land, which has led to the exploration of the oceans to findnew tests and cures for illnesses. Entire classes of antibiotics desperately needed for a worldsurviving on relatively few antibiotics, which people are becoming resistant to, could befound in just a few marine samples.The report Global Markets for Marine-Derived Pharmaceuticals describes the potential ofmarine research and its growth prospects. It is estimated that marine-derived drugs willessentially double in number from 2011 to 2016. Because marine-derived drugs alreadyaccount for a few powerful drugs, this area of the drug industry has already generatedbillions of dollars to date.SCOPE OF REPORTThe scope of this study encompasses research organizations, the U.S. government chiefly inthe form of the National Cancer Institute (NCI), and companies that develop or help in thedevelopment process of pharmaceuticals derived from marine life. Included are extensivedescriptions, perspectives, and predictive information, including forecasts of growth over the
next 5 years. Technological issues, including the latest trends, are discussed.INTENDED AUDIENCEIn this report, marine-derived pharmaceuticals are described in terms of their history inmedicine, technology types and categories, research organizations, major companies,impact on the pharmaceutical market, applications, current market values, growth potential,and significant trends. This study will be of interest to non-profits and the governmentsector as well as the biotechnology and pharmaceutical industries and related life science,analytics, drug discovery, and diagnostic test manufacturing companies as well as all thoseinterested in or actively working in drug and imaging agent research and investors in all ofthe above.METHODOLOGYBCC presents an analysis of the types of technologies, applications, and therapeutic areasrepresenting the financial value of marine-derived pharmaceuticals. Estimated values arebased on actual aggregate sales for the years discussed. Information, in general, iscompiled through a combination of primary and secondary research, including annualreports and interviews with company and government officials as well as experts inacademia.INFORMATION SOURCESBCC’s analysis includes the review of more than 50 companies and information fromfinancial and trade publications as well as the U.S. Food and Drug Administration (FDA).Included were pharmaceutical and biotechnology companies as well as support companiesto them.ABOUT THE AUTHORKim Lawson is a graduate of Mount Holyoke College with a degree in English Literature. Sheacquired experience as a healthcare journalist, including working for John Wiley & Sons foryears as a print reporter, before serving as a research analyst in a small market researchfirm that focused on pharmaceuticals and biotechnology in the Research Triangle Park areaof North Carolina. Before joining that firm, Kim published two reports on emerging andestablished diagnostics and therapeutics for benign and cancerous breast disease.|Table Of ContentsChapter- 1: INTRODUCTION - ComplimentarySTUDY GOALS AND OBJECTIVESREASONS FOR DOING THIS STUDYSCOPE OF REPORTINTENDED AUDIENCEMETHODOLOGYINFORMATION SOURCES
ABOUT THE AUTHORRELATED BCC REPORTSBCC ONLINE SERVICESDISCLAIMERChapter- 2: EXECUTIVE SUMMARYINVESTMENT AND PATH FORWARDKEY DRIVERSKEY CHALLENGESKEY TRENDSINVESTMENT LANDSCAPEChapter- 3: OVERVIEWHISTORY OF MARINE DRUGSMAJOR CATEGORIES OF MARINE DRUGSChapter- 4: MARKET LANDSCAPECOMMERCIALIZED MARINE LIFE DRUGS BY TYPEPHARMACEUTICAL MARKET IN GENERALMARINE-DERIVED DRUG LANDSCAPECOMMERCIALIZATION LANDSCAPE BY 2016MECHANISMS OF ACTIONMARINE DRUG CULTIVATIONREGULATORY ENVIRONMENTPATENTSMARINE DRUG DEVELOPMENT: AREAS OF FOCUS TO WATCHMARINE DRUG DEVELOPMENT RESEARCHDISEASES/CONDITIONS MOST OFTEN TREATED WITH MARINE DRUGSChapter- 5: COMPANY PROFILESABBOTT LABORATORIESAFFIRIS AGAKER BIOMARINE ASAALGENICSAPHIOS CORP.APP PHARMACEUTICALSARCTICZYMESASKA PHARMACEUTICAL CO., LTD.ASTELLAS (AGENSYS, INC.)AQUAPHARM BIODISCOVERY, LTD.AZUR PHARMABASF SEBAYER INNOVATIONBEDFORD LABORATORIESBIOSYN CORP.BIOVEST INTERNATIONAL, INC.BTG INTERNATIONAL, LTD.CATABASIS PHARMACEUTICALS, INC.CELLDEX THERAPEUTICSCENTOCOR ORTHO BIOTECHCOGNETIX, INC.
Table 28 : MARINE RESEARCH RESOURCES BY CATEGORYTable 29 : KEY RESEARCHERS/LEADERS AFFECTING MARINE-DERIVED DRUG INDUSTRYList of TablesSummary Table : GLOBAL FORECAST FOR MARINE-DERIVED DRUGS BY TYPE, THROUGH2016Table 1 : KEY DATES IN MARINE-DERIVED DRUG HISTORYTable 2 : GROWTH IN THE INTEREST IN MARINE NATURAL PRODUCTS BASED ON THENUMBER OF PRODUCTS DESCRIBED IN SCIENTIFIC JOURNALS, 1999–2004Table 3 : TOP 10 PHARMA IN SALES IN 2010Table 4 : PHARMAMAR R&D PIPELINE IN THE U.S., 2011Table 5 : MARINE-DERIVED DRUGS APPROVED AND IN LATE-STAGE DEVELOPMENT*, 2011Table 6 : MARINE-DERIVED DRUGS/DRUG CANDIDATE’S MECHANISM OF ACTIONTable 7 : KEY MARINE-DERIVED PRODUCT LIBRARIESTable 8 : KEY MARINE-DERIVED DRUG RESEARCH CANDIDATES: COMPOUNDS BY DRUGTYPETable 9 : GLOBAL PHASE III PIPELINE FOR BREAST CANCER THROUGH 2016Table 10 : GLOBAL PHASE III PIPELINE FOR BRAIN OR CNS CANCER, THROUGH 2016Table 11 : GLOBAL PHASE III PIPELINE FOR BLADDER CANCER, THROUGH 2016Table 12 : GLOBAL PHASE III PIPELINE FOR COLORECTAL CANCER, THROUGH 2016Table 13 : GLOBAL PHASE III PIPELINE FOR HEAD AND NECK CANCER, THROUGH 2016Table 14 : GLOBAL PHASE III PIPELINE FOR KIDNEY CANCER, THROUGH 2016Table 15 : GLOBAL PHASE III PIPELINE FOR LEUKEMIA, THROUGH 2016Table 16 : GLOBAL PHASE III PIPELINE FOR LIVER CANCER THROUGH 2016Table 17 : GLOBAL PHASE III PIPELINE FOR LUNG CANCER THROUGH 2016Table 18 : GLOBAL PHASE III PIPELINE FOR LYMPHOMA, THROUGH 2016Table 19 : GLOBAL PHASE III PIPELINE FOR MULTIPLE MYELOMA, THROUGH 2016Table 20 : GLOBAL PHASE III PIPELINE FOR OVARIAN CANCER, THROUGH 2016Table 21 : GLOBAL PHASE III PIPELINE FOR PANCREATIC CANCER, THROUGH 2016Table 22 : GLOBAL PHASE III PIPELINE FOR PROSTATE CANCER, THROUGH 2016Table 23 : GLOBAL PHASE III PIPELINE FOR SARCOMA, THROUGH 2016Table 24 : GLOBAL PHASE III PIPELINE FOR SKIN CANCER, THROUGH 2016Table 25 : GLOBAL PHASE III PIPELINE FOR SOLID TUMORS, THROUGH 2016Table 26 : GLOBAL PHASE III PIPELINE FOR STOMACH CANCER, THROUGH 2016Table 27 : GLYCOMAR POLYSACCHARIDE CHARACTERIZATION SERVICESTable 28 : MARINE RESEARCH RESOURCES BY CATEGORYTable 29 : KEY RESEARCHERS/LEADERS AFFECTING MARINE-DERIVED DRUG INDUSTRYList of FiguresSummary Figure : GLOBAL FORECAST FOR MARINE-DERIVED DRUGS, 2010-2016Figure 1 : THE TUNICATE ECTEINASCIDIA TURBINATE FROM WHICH YONDELIS(TRABECTEDIN) FOR CANCER TREATMENT IS MADEFigure 2 : MARINE SPECIES PER PHYLUM BASED ON WORMSFigure 3 : APPROXIMATION OF KNOWN VERSUS POSSIBLE SPECIES WITHIN THREE PHYLA,2011Figure 4 : COMMERCIALIZED MARINE DRUGS BY MARINE LIFE TYPE, 2011 AND 2016Figure 5 : COMMERCIALIZED MARINE DRUGS*, 2010–2016Figure 6 : GLOBAL FORECAST FOR MARINE-DERIVED DRUGS* BY THERAPEUTICCATEGORY, 2009-2016
Figure 7 : COMMERCIALIZED MARINE DRUGS BY THERAPEUTIC AREA, 2011Figure 8 : COMMERCIALIZED MARINE DRUGS BY MARINE LIFE TYPE, 2016Figure 9 : GLOBAL PHARMACEUTICAL DRUG SALES, 2010Figure 10 : GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL SALES, 2010 AND 2016Figure 11 : MARINE SAMPLE/MOLECULE CULTIVATION AND PROCESSINGAbout Us:ReportsnReports is an online library of over 100,000+ market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: email@example.com://www.reportsnreports.comVisit our Market Research Blog